KLIC Q2 Results Beat; Recovery Underway but Valuation Remains Stretched

What happened

Kulicke & Soffa reported Q2 FY2026 revenue of $242.6M and non-GAAP EPS of $0.79, well above the prior year's depressed levels and reflecting the post-EA shutdown margin recovery. The company benefited from a strong mix shift and the absence of EA charges, with gross margin likely in the mid-to-high 40s. While this confirms the cyclical inflection the master report anticipated, the reported TCB revenue component—key to the AI/HBM thesis—is not separately disclosed, leaving the premium story unverified. The results suggest the base case recovery is on track, but the stock's elevated multiple (trailing P/E still triple-digit on a full-year basis) leaves no room for disappointment. Investors should recognize that execution is improving, but the risk/reward remains balanced given the lack of detail on the advanced packaging ramp and persistent China concentration.

Implication

The strong Q2 results support the base case scenario of revenue recovery to ~$750M with mid-40s gross margins. However, the lack of explicit TCB revenue disclosure means the AI/HBM premium story remains unproven. If upcoming quarters show TCB revenue approaching the $100M target, the bull case becomes more credible, potentially justifying the current valuation. Until then, the risk/reward is symmetric, and positioning should be sized accordingly. The company's net cash and free cash flow provide a floor, but the high multiple limits upside without clear advanced packaging wins.

Thesis delta

The previous 'WAIT' rating was predicated on needing hard evidence of the AI/advanced packaging ramp. Q2's strong headline numbers provide partial evidence of the cyclical recovery but not the specific TCB traction. Therefore, the thesis shifts from 'wait for any recovery' to 'wait for TCB proof'—a narrower but still unresolved condition.